Page 127 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

15. Miyamoto S, Hasegawa J, Morioka M, Hirota Y, Kushima M, Sekizawa A. The association between p16 and Ki67 immunohistostaining and the progression of cervical intraepithelial neoplasia grade 2. Int J Gynaecol Obstet. 2016;134(1):45-8.
16. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373-80.
17. Koeneman MM, van Lint FHM, van Kuijk SMJ, Smits LJM, Kooreman LFS, Kruitwagen R, et al. A prediction model for spontaneous regression of cervical intraepithelial neoplasia grade 2, based on simple clinical parameters. Hum Pathol. 2017;59:62-9.
18. Fonseca-Moutinho JA. Smoking and cervical cancer. ISRN Obstet Gynecol. 2011;2011:847684.
19. Guillaud M, Buys TP, Carraro A, Korbelik J, Follen M, Scheurer M, et al. Evaluation of HPV infection and smoking status impacts on cell proliferation in epithelial layers of cervical
neoplasia. PLoS One. 2014;9(9):e107088. 6
20. Samir R, Asplund A, Tot T, Pekar G, Hellberg D. Tissue tumor marker expression in smokers, including serum cotinine concentrations, in women with cervical intraepithelial neoplasia
or normal squamous cervical epithelium. Am J Obstet Gynecol. 2010;202(6):579 e1-7.
21. Wang C, Gu W, Zhang Y, Ji Y, Wen Y, Xu X. Nicotine promotes cervical carcinoma cell line HeLa migration and invasion by activating PI3k/Akt/NF-kappaB pathway in vitro. Exp Toxicol
Pathol. 2017;69(6):402-7.
22. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, et al. Role of parity and
human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet.
2002;359(9312):1093-101.
23. International Collaboration of Epidemiological Studies of Cervical C. Cervical carcinoma
and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer. 2006;119(5):1108-24.
24. Jensen KE, Schmiedel S, Norrild B, Frederiksen K, Iftner T, Kjaer SK. Parity as a cofactor for high-grade cervical disease among women with persistent human papillomavirus infection: a 13-year follow-up. Br J Cancer. 2013;108(1):234-9.
25. Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, et al. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants. Cancer Epidemiol Biomarkers Prev. 2009;18(1):113-20.
26. Kim JW, Song SH, Jin CH, Lee JK, Lee NW, Lee KW. Factors affecting the clearance of high-risk human papillomavirus infection and the progression of cervical intraepithelial neoplasia. J Int Med Res. 2012;40(2):486-96.
27. Ismail SM, Colclough AB, Dinnen JS, Eakins D, Evans DM, Gradwell E, et al. Observer variation in histopathological diagnosis and grading of cervical intraepithelial neoplasia. BMJ. 1989;298(6675):707-10.
28. Carreon JD, Sherman ME, Guillen D, Solomon D, Herrero R, Jeronimo J, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007;26(4):441-6.
Prognostic factors for hrHPV positive CIN2
125